MCRB vs. FGEN, NKTR, CDMO, CYRX, YMAB, SIGA, ALT, HRTX, CMPS, and TRDA
Should you be buying Seres Therapeutics stock or one of its competitors? The main competitors of Seres Therapeutics include FibroGen (FGEN), Nektar Therapeutics (NKTR), Avid Bioservices (CDMO), Cryoport (CYRX), Y-mAbs Therapeutics (YMAB), SIGA Technologies (SIGA), Altimmune (ALT), Heron Therapeutics (HRTX), COMPASS Pathways (CMPS), and Entrada Therapeutics (TRDA). These companies are all part of the "pharmaceutical preparations" industry.
Seres Therapeutics (NASDAQ:MCRB) and FibroGen (NASDAQ:FGEN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, media sentiment, valuation, community ranking, earnings and analyst recommendations.
59.3% of Seres Therapeutics shares are held by institutional investors. Comparatively, 72.7% of FibroGen shares are held by institutional investors. 5.1% of Seres Therapeutics shares are held by insiders. Comparatively, 2.0% of FibroGen shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Seres Therapeutics currently has a consensus price target of $5.00, indicating a potential upside of 426.21%. FibroGen has a consensus price target of $17.00, indicating a potential upside of 1,254.58%. Given FibroGen's higher probable upside, analysts plainly believe FibroGen is more favorable than Seres Therapeutics.
In the previous week, FibroGen had 1 more articles in the media than Seres Therapeutics. MarketBeat recorded 6 mentions for FibroGen and 5 mentions for Seres Therapeutics. FibroGen's average media sentiment score of 1.40 beat Seres Therapeutics' score of 0.87 indicating that FibroGen is being referred to more favorably in the news media.
Seres Therapeutics has a net margin of 0.00% compared to FibroGen's net margin of -143.57%.
Seres Therapeutics has higher earnings, but lower revenue than FibroGen. Seres Therapeutics is trading at a lower price-to-earnings ratio than FibroGen, indicating that it is currently the more affordable of the two stocks.
Seres Therapeutics received 181 more outperform votes than FibroGen when rated by MarketBeat users. Likewise, 72.48% of users gave Seres Therapeutics an outperform vote while only 62.36% of users gave FibroGen an outperform vote.
Seres Therapeutics has a beta of 2.16, meaning that its share price is 116% more volatile than the S&P 500. Comparatively, FibroGen has a beta of 0.88, meaning that its share price is 12% less volatile than the S&P 500.
Summary
Seres Therapeutics beats FibroGen on 11 of the 17 factors compared between the two stocks.
Get Seres Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MCRB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MCRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Seres Therapeutics Competitors List
Related Companies and Tools
